Alzheimer's drug developer Cassava Sciences (NASDAQ:SAVA) has struck a consulting agreement with its former chief executive officer, Remi Barbier, nearly two months after his resignation. The ...
Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the Alzheimer’s disease world is being exposed and will hopefully get cleaned up. Remi Barbier, Cassava’s longtime CEO, has ...
Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results